Timothy R. Wright
Net Worth
Last updated:
What is Timothy R. Wright net worth?
The estimated net worth of Mr. Timothy R. Wright is at least $18,455,117 as of 9 Jun 2022. He owns shares worth $12,150,400 as insider, has earned $904,717 from insider trading and has received compensation worth at least $5,400,000 in MiMedx Group, Inc..
What is the salary of Timothy R. Wright?
Mr. Timothy R. Wright salary is $1,350,000 per year as Chief Executive Officer & Director in MiMedx Group, Inc..
How old is Timothy R. Wright?
Mr. Timothy R. Wright is 67 years old, born in 1958.
What stocks does Timothy R. Wright currently own?
As insider, Mr. Timothy R. Wright owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| MiMedx Group, Inc. (MDXG) | Chief Executive Officer & Director | 1,711,324 | $7.1 | $12,150,400 |
What does MiMedx Group, Inc. do?
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Timothy R. Wright insider trading
MiMedx Group, Inc.
Mr. Timothy R. Wright has made 4 insider trades between 2021-2022, according to the Form 4 filled with the SEC. Most recently he sold 112,000 units of MDXG stock worth $420,000 on 9 Jun 2022.
The largest trade he's ever made was exercising 112,000 units of MDXG stock on 9 Jun 2022. As of 9 Jun 2022 he still owns at least 1,711,324 units of MDXG stock.
MiMedx Group key executives
MiMedx Group, Inc. executives and other stock owners filed with the SEC:
- Dr. Robert Benjamin Stein M.D., Ph.D. (74) Executive Vice President of R&D
- Dr. Rohit Kashyap Ph.D. (54) Executive Vice President & Chief Commercial Officer
- Mr. Peter Martin Carlson CPA (61) Chief Financial Officer
- Mr. Timothy R. Wright (67) Chief Executive Officer & Director
- Mr. William F. Hulse IV (51) Gen. Counsel & Sec.